Contract manufacturing organisations (CMOs) have been busy in the past week, with OsoBio expanding its plant and AMRI adopting a new relationship strategy.
OSO BioPharmaceuticals has invested $5m (€4m) in an aseptic filling suite. The additions to the facility, such as the rolling diaphragm pump from Bosch, allow it to operate at 115 per cent of the previous line’s capacity
Milton Boyer, president of OsoBio, said: “This state-of-the-art filling suite represents a substantial investment in the future – the future of OsoBio, as well as the futures of the pharmaceutical clients we serve.
“It allows OsoBio to manufacture drugs in a better, smarter and faster manner, while ensuring high-quality product and the safety of patients and employees alike. This is an exciting new addition to OsoBio’s facility.”
AMRI has adopted an approach, which it calls SmartSourcing, to better meet the changing needs of the biopharma industry. By pursuing the strategy AMRI says it will open itself up to more innovative models for outsourcing relationships.
“Pharma companies are looking for more supplier accountability, greater trust and consultation. They want a better balance of risk, but also greater flexibility and tailored business models that address their unique needs,” Thomas D'Ambra, president and CEO of AMRI, said.
“With SmartSourcing, we offer customers innovative and strategic collaborative partnerships, without compromising quality or lowering expectations. We look forward to working with our customers as we continue to provide creative and flexible outsourcing solutions.”
Depending on the needs of the client AMRI will offer insourcing, like it does for Eli Lilly, outsourcing, or a combination of the two. AMRI hopes this flexibility will prove attractive to biopharma companies trying to cut their fixed costs and move to a more efficient drug development and manufacturing model.